OMNIPAQUE 350 755 MG — DIN 02172755
IOHEXOL : 755 MG · GE HEALTHCARE CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OMNIPAQUE 350?
OMNIPAQUE 350 755 MG contains IOHEXOL : 755 MG. It is listed in the Health Canada Drug Product Database under DIN 02172755, held by GE HEALTHCARE CANADA INC, supplied as SOLUTION for INTRAVASCULAR ; ORAL administration. Health Canada currently lists it as marketed, status dated 29-Dec-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OMNIPAQUE 350 used for?
Radiographic contrast medium for myelography, angiocardiography, CT enhancement, arteriography, venography, urography, arthrography, and GI tract imaging.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Iohexol cost around the world?
Iohexol is listed on 6 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Hungary publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 6 | 28 | SAR███.██ |
| Hungary | producer price (ex-factory) | 3 | 14 | HUF███.██ |
| Iceland | max wholesale | 1 | 10 | ISK███.██ |
| South Africa | single exit price | 9 | 9 | ZAR███.██ |
| Bahrain | retail (max) | 2 | 7 | BHD███.██ |
| Romania | max producer price | 2 | 3 | RON███.██ |
71 pack listings across 23 brand entries and 6 price bases, refreshed 03 Sep 2026. Ranges span every Iohexol pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Iohexol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Iohexol, across 8 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GE HEALTHCARE CANADA INC | 4 | 3 | OMNIPAQUE 180, OMNIPAQUE 240, OMNIPAQUE 300, OMNIPAQUE 350 | Sourceable in Canada |
| SANOFI CANADA, INC. | 4 | 0 | OMNIPAQUE 180 LIQ SAR 388MG/ML, OMNIPAQUE 240 LIQ IV SAR 518MG/ML, OMNIPAQUE 300 LIQ IV SAR 647MG/ML, OMNIPAQUE 350 LIQ IV 755MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 755 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVASCULAR ; ORAL |
| Pack configuration (monograph) | Vials and bottles (specific sizes not listed in provided text excerpt). |
| Storage | Protect from light. (Specific temperature range not in excerpt, but usually 15-30°C for this class). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Iohexol |
|---|---|
| ATC code | V08AB02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02172755 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2172755 |
| Brand name | OMNIPAQUE 350 |
| Generic / active ingredient | IOHEXOL : 755 MG |
| Market authorization holder | GE HEALTHCARE CANADA INC |
| Health Canada schedule | Ethical |
| ATC code | V08AB02 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08AB |
| Current status | MARKETED |
| Status date | 29-Dec-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Dosage varies by procedure and patient age. Administered via subarachnoid, intravascular, oral, rectal, or intra-articular routes. Inject at or close to body temperature.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to iohexol or any ingredient; clinically significant impairment of both hepatic and renal function.
Warnings and precautions
Serious/fatal anaphylactoid reactions possible. Observe for 30 mins. Risk of neurological complications if blood-brain barrier is disrupted. Avoid intracranial entry of bolus in myelography.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 8 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMNIPAQUE 240 | 518 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | 02172739 |
| OMNIPAQUE 300 | 647 MG | SOLUTION | GE HEALTHCARE CANADA INC | MARKETED | 02172747 |
| OMNIPAQUE 180 | 388 MG | SOLUTION | GE HEALTHCARE CANADA INC | CANCELLED POST MARKET | 02172720 |
| OMNIPAQUE 180 LIQ SAR 388MG/ML | 180 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | 02018098 |
| OMNIPAQUE 240 LIQ IV SAR 518MG/ML | 240 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | 02018101 |
| OMNIPAQUE 300 LIQ IV SAR 647MG/ML | 300 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | 02018128 |
| OMNIPAQUE 350 LIQ IV 755MG/ML | 350 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | 02018136 |
2 · Same class — other molecules in ATC V08AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Iopamidol | IOPAMIDOL INJECTION USP · ISOVUE 128 INJ 26% · ISOVUE 128 INJECTION · ISOVUE 200 INJ 41% · +8 more | 15 | 5 | Yes |
| Iodixanol | IODIXANOL INJECTION 270 · IODIXANOL INJECTION 320 · VISIPAQUE 270 · VISIPAQUE 320 | 4 | 4 | Yes |
| Iohexol | OMNIPAQUE 180 · OMNIPAQUE 180 LIQ SAR 388MG/ML · OMNIPAQUE 240 · OMNIPAQUE 240 LIQ IV SAR 518MG/ML · +4 more | 8 | 3 | Yes |
| Iopromide | ULTRAVIST 240 · ULTRAVIST 300 · ULTRAVIST 370 | 3 | 2 | Yes |
| Ioversol | OPTIRAY 160 · OPTIRAY 160 (ULTRAJECT) · OPTIRAY 240 · OPTIRAY 240 (ULTRAJECT) · +7 more | 11 | 0 | Not in Canada |
| Iotrolan | OSMOVIST 240 - LIQ INT 513MG/ML · OSMOVIST 300 - LIQ INT 641MG/ML | 2 | 0 | Not in Canada |
| Ioxaglic Acid | HEXABRIX 200 · HEXABRIX 320 | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V08A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V08AA | Diatrizoic Acid · Iotalamic Acid · Ioxitalamic Acid · Watersol., Nephrotropic, High Osm. X-Ray Contr. Media | 41 | 1 |
| V08AD | Ethyl Esters Of Iodised Fatty Acids · Iopydol | 2 | 1 |
| V08AC | Adipiodone · Iopanoic Acid · Sodium Iopodate | 6 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OMNIPAQUE 350 called?
The same molecule, Iohexol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Omnipaque | Latin | Bahrain, Iceland, Saudi Arabia |
| Illusof | Latin | Bahrain, Saudi Arabia |
| Iohexol PPI | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.